We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Advanced Blood Test Helps Improve Cancer Treatments

By LabMedica International staff writers
Posted on 02 Jul 2024
Print article
Image: The new test analyzes gene fragments in the bloodstream (Photo courtesy of 123RF)
Image: The new test analyzes gene fragments in the bloodstream (Photo courtesy of 123RF)

Early detection of cancer significantly increases the likelihood of successful treatment across various cancer types. In addition to personalized evaluation of therapy benefits and risks, continuous monitoring of treatment success is vital. Traditionally, oncologists rely on imaging technology and invasive procedures such as tissue biopsies, punctures, and endoscopic measures to monitor patients. Now, researchers have further developed an advanced method, a type of liquid biopsy that utilizes blood samples rather than direct tissue sampling for detecting various types of cancer.

The technique, developed by researchers at the University of Zurich (UZH, Zurich, Switzerland) and the University Hospital Zurich (USZ, Zurich, Switzerland), involves sequencing and analyzing DNA fragments that circulate in the blood of patients to identify changes specific to particular cancers. The research team examined alterations in the number and length distribution of the DNA fragments, enabling them to distinguish between biologically less and more aggressive metastatic cancers even earlier than traditional imaging methods.

In their study, the researchers applied this method to patients undergoing radiotherapy, including some affected by the human papillomavirus (HPV), known to cause certain cancers. By measuring the concentration of HPV DNA fragments in the blood, they could track tumor development. For head and neck cancer specifically, high levels of HPV DNA in the blood were identified as a possible early indicator of cancer recurrence, suggesting the potential use of immunotherapy as a treatment response.

This novel liquid biopsy technique holds promise for risk assessment, treatment monitoring during follow-ups, and early detection of cancer recurrence for all tumor types. Its non-invasive nature, relying on blood samples rather than tissue biopsies, makes it less burdensome and more feasible for routine use in clinical settings. This method reduces the need for frequent diagnostic procedures, reducing long waiting periods for patients. By providing a more accurate evaluation of tumor activity and progression, this approach can significantly aid oncologists in designing personalized treatment plans tailored to individual patient needs.

“Our method can be used in the future for risk assessments, treatment monitoring during follow-up care and early detection of cancer recurrence, in principle for all types of tumors,” said Zsolt Balázs from the UZH Department of Quantitative Biomedicine, who is co-first author of the study published in Radiotherapy and Oncology. “We can see earlier and more quickly how much the cancer has spread in the body and how well a patient is responding to a specific treatment, or whether there will be a relapse.”

Related Links:
University of Zurich
University Hospital Zurich

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.